Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia

Open access
Javitt, D. C., Zukin, S. R., Heresco-Levy, U., Umbricht, D. · 2012 · Schizophrenia Bulletin

Abstract

Over the last 20 years, glutamatergic models of schizophrenia have become increasingly accepted as etiopathological models of schizophrenia, based on the observation that phencyclidine (PCP) induces a schizophrenia-like psychosis by blocking neurotransmission at N-methyl-D-aspartate (NMDA)-type glutamate receptors. This article reviews developments in two key predictions of the model: first, that neurocognitive deficits in schizophrenia should follow the pattern of deficit predicted based on underlying NMDAR dysfunction and, second, that agents that stimulate NMDAR function should be therapeutically beneficial. As opposed to dopamine receptors, NMDAR are widely distributed throughout the brain, including subcortical as well as cortical brain regions, and sensory as well as association cortex. Studies over the past 20 years have documented severe sensory dysfunction in schizophrenia using behavioral, neurophysiological, and functional brain imaging approaches, including impaired generation of key sensory-related potentials such as mismatch negativity and visual P1 potentials. Similar deficits are observed in humans following administration of NMDAR antagonists such as ketamine in either humans or animal models. Sensory dysfunction, in turn, predicts impairments in higher order cognitive functions such as auditory or visual emotion recognition. Treatment studies have been performed with compounds acting directly at the NMDAR glycine site, such as glycine, D-serine, or D-cycloserine, and, more recently, with high-affinity glycine transport inhibitors such as RG1678 (Roche). More limited studies have been performed with compounds targeting the redox site. Overall, these compounds have been found to induce significant beneficial effects on persistent symptoms, suggesting novel approaches for treatment and prevention of schizophrenia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/schbul/sbs069

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 76 references

Research works printed but not linked: 4

  1. Javitt, 1987, The Hillside journal of clinical psychiatry, 9, 12
  2. 2011, Science Translational Medicine, 3, 102mr102
  3. Javitt, 2009, Current opinion in drug discovery & development, 12, 468
  4. 2010, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 35, s320

Cited by

See all 322

Metadata

Authors
Javitt, D. C., Zukin, S. R., Heresco-Levy, U., & Umbricht, D.
Affiliations
  • Nathan Kline Institute for Psychiatric Research (US)
  • Johns Hopkins University (US)
  • F. Hoffmann-La Roche AG (CH)
Corresponding author
Javitt, D. C.
Venue
Schizophrenia Bulletin
Published
2012-09-01
Volume
38
Issue
5
Pages
958-966
ISSN
  • 0586-7614 (ISSN-L)
  • 1745-1701
OpenAlex
W2165209294
Cited by
322
References
76
Citations by year
2026: 2 · 2025: 13 · 2024: 15 · 2023: 11 · 2022: 20 · 2021: 21 · 2020: 26 · 2019: 40 · 2018: 20 · 2017: 22 · 2016: 27 · 2015: 38 · 2014: 36 · 2013: 29 · 2012: 2
FWCI
4.53
Type
journal article
Language
en
Open access
Locations
  • Schizophrenia Bulletin (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute of Mental Health (R37MH049334, R37MH49334, P50MH086385, R01MH049334)
  • National Institute on Drug Abuse (R01DA03383, R01DA003383)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
schizophrenia, NMDA receptor hypofunction
MeSH terms
Animals, Brain, Brain Mapping, Cerebral Cortex, Cognition Disorders, Contingent Negative Variation, Disease Models, Animal, Drug Synergism, Glycine, Hippocampus, Humans, Ketamine, Synaptic Transmission, Perception, Phencyclidine, Psychoses, Substance-Induced, Schizophrenia, Antipsychotic Agents, Receptors, N-Methyl-D-Aspartate, Receptors, Dopamine D2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia. https://app.cochat.ai/papers/10.1093/schbul/sbs069
The paper
Javitt, D. C., Zukin, S. R., Heresco-Levy, U., & Umbricht, D. (2012). Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbs069

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.